Background: Neuroblastoma (NB) is remarkable for its wide spectrum of clinical behavior and biological characteristics in relation to outcome. The use of aggressive therapy, including autologous hematopoietic stem cell transplantation (HSCT) and the addition of isoretionin (cis-Retinoic Acid/cis-RA), has increased survival rates of patients with advanced disease. Methods: Pediatric 271 newly diagnosed high risk NB patients were prospectively enrolled into the study. Patients received neoadjuvant chemotherapy of alternating cycles: [cyclophosphamide, doxorubicin, vincristine (CAdO)] and [etoposide, carboplatin]. Intensification courses of "ICE" (ifosfamide, carboplatin, and etoposide) regimen were administered to patients with bone marrow (BM) residual infiltration. Whenever safely feasible, complete surgical resection or debulking of the primary tumor was attempted for patients achieving partial response. Eligible patients underwent HSCT, while radiation therapy to the primary and metastatic sites, as well as maintenance with cis-RA was given for 6 months. Results: The median age of our patients was 2.8 years with male to female ratio of 1.65:1. At 4 years, the overall and event free survivals were 33.7% and 23.3% for the entire group under study, with significantly higher rates (42.7% and 35.6%, respectively) for HSCT patients (n = 94; p < 0.001). The outcome was also significantly correlated with response to induction therapy, pathological subtype, as well as other variables. Conclusion: Myeloablative therapy followed by stem cell rescue is regarded as the most important goal of high risk NB treatment to improve survival till present. Each of consolidation HSCT, post induction disease status, as well as international neuroblastoma pathology classification (INPC) subtype was an independent predictive variable of survival. A collaborative effort with an emphasis on biologic characteristics of aggressive disease and tailored therapy needs to be strengthened to further our understanding of this disease.
Introduction
Neuroblastoma (NB) accounts for more than 8% of malignancies in patients younger than 15 years of age, and is responsible for 15% of all pediatric oncology deaths [1] . The disease is remarkable for its wide spectrum of clinical behavior. Although substantial improvement in outcome occurred in lower risk categories during the past few decades, the outcome for children with a high-risk (HR) disease has been improved only modestly having less than 40% long-term survival rates [2] . It is generally believed that biological characteristics are more relevant to the outcome in advanced NB than the type of chemotherapy or extent of resection [3] . However, the use of aggressive chemotherapy increased the survi-val rates of patients with advanced NB [4] . Myeloablative therapy and autologous hematopoietic stem cell rescue can significantly result in a better 5-year Overall Survival (OS) and Event Free Survival (EFS) than nonmyeloablative chemotherapy. While adding isoretionin (cis-Retinoic Acid/cis-RA) to consolidation therapy independently resulted in a significantly improved OS; analysis of consecutive trials from a single center demonstrated that combining cis-RA with monoclonal antibody (MoAb 3F8), and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) has also improved survival significantly in HR-NB [5, 6] . Chemotherapy dose-escalation strategy using tandem autologous Hematopoietic Stem Cell Transplantation (HSCT) was also encouraging for survival [7] . Other new chemotherapeutic agents such as irinotecan and paclitaxel are also evaluated in the treatment of advanced and refractory NB by ongoing clinical trials, however, further studies incorporating newer modalities are still required as well to reduce late adverse effects without jeopardizing survival outcome [8] .
The purpose of this study was to evaluate the outcome of HR-NB in Egyptian children treated with aggressive multimodality approach that included HSCT and cis-RA.
Patients and Methods

Patients
Newly diagnosed and treated pediatric NB patients at The Children's Cancer Hospital-Egypt (CCHE/57357) were prospectively enrolled onto study from July 2007 till December 2011. The international criteria were used for risk stratification (International Neuroblastoma Staging System/INSS), and assessment of disease response defined as; complete response (CR), very good partial response (VGPR), partial response (PR), no response (NR), progressive disease (PD) or mixed response (MR); according to the International Neuroblastoma Response Criteria (INRC) [9] . Data was timely updated and analyzed at different checkpoints throughout study period.
Workup
 Tissue samples were processed and routinely stained with hematoxylin and eosin stain. Tissues were diagnosed as neuroblastoma and were classified histologically as poorly differentiated, undifferentiated or differentiating while ganglioneuroblastoma (GNB) were classified as nodular or intermixed. Tumor was classified according to the international neuroblastoma pathology classification (INPC/modified Shimada) into favorable or unfavorable; based on histology, mitosis/karyorrhexis index, and age [10] . Immunostains using BenchMark XT Ventana automated slide staining system were used either for confirmation; synaptophysin (most consistent in our lab), creatinine clearance ≥ 60 mL/min/1.73 m² and a serum creatinine ≤ 1.5 mg/dl.  Normal cardiac function: ejection fraction ≥55% and fractional shortening ≥28% documented by echocargram.  Informed consent: the patient's legally authorized guardian must acknowledge in writing that consent to receive chemotherapy, radiotherapy and surgery has been obtained, in accordance with local policies for CCHE.
Off Protocol Criteria
 Progressive disease/no response on protocol therapy.  Treatment limiting organ dysfunction.
Treatment Plan
Patients were started on upfront induction chemotherapy with "cyclophosphamide, doxorubicin, vincristine (CAdO)" alternating with "carboplatin and etoposide" for 6 cycles [13] . Patients failed to have their BM cleared of metastatic disease by end of upfront regimen or had less than PR after 4 cycles, were upgraded to receive additional 2 -4 intensification courses of "ICE" [ifosfamide: 1800 mg/m 2 /d (d1 -d5), carboplatin: 560 mg/m 2 (d1), and etoposide: 100 mg/m 2 /d (d1 -d5)]; guided with response. When safely feasible, surgical resection or debulking of the primary tumor was attempted between 5th and 6th chemotherapy cycles for patients achieved PR. By end of induction, consolidation with autologous HSCT was offered to eligible patients with at least PR and had their BM cleared of disease unless denied by parents. Radiation therapy was consistently delivered to the primary as well as postinduction MIBG avid metastatic bony sites. Maintenance cis-RA was given for 14 days q monthly at 160 mg/m 2 /day for 6 months following HSCT or post induction for non transplant patients attained CR/VGPR/PR [14] .
Statistical Analysis
All data were analyzed using SPSS 16.0 software (SPSS, Chicago, IL, USA). Correlations were analyzed using χ 2 test. OS was calculated from date of diagnosis to the date of death for any cause, and EFS was defined as the time from diagnosis to the time of first occurrence of relapse, progression, or death.
The Kaplan-Meier curves were plotted to calculate 5-year survival curves, and log-rank test was used to estimate the differences. Factors known to be associated with prognosis were tested in univariate analysis. Variables that were found to be significant in univariate analysis were then entered in a multivariate Cox proportional hazards regression model to identify those with independent prognostic information for EFS and OS. The "P" value was defined as statistically significant if < 0.05.
Results
Two hundreds and seventy one patients were enrolled during our study period. Patients age ranged between 2 months and 12.7 years (Median: 2.8 years) at time of diagnosis; 169 males (62.4%) and 102 females (37.6%) with a ratio of 1.65:1.
Histologically, NB was confirmed in 251 patients (92.6%); 200 cases were unfavorable according to INPC with poorly differentiated morphology, while GNB was seen in 14 patients (5.2%). Diagnosis was established in another 6 patients (2.2%) by infiltrated BM biopsy and elevated urinary VMA. As regards NMYC gene status, 82 of studied cases showed an amplified gene ( Figure 1) ; 2/82 showed mosaic pattern.
Abdominal tumor was the most common primary site of disease found in 245 of the study patients (90.4%), with adrenal origin seen in 190 patients (70.1%) while 55 (20.3%) had extra-adrenal locations. BM was the most common site of metastasis which seen in 53.5% of patients. Clinicopathological data are presented in Table 1 .
Local surgical control (complete/partial) was feasible in 157 patients. Due to early death or lost follow up, 23 patients were not evaluable for induction response whereas disease status for 248/271 evaluable patients showed: 4 CR (1.6%), 14 VGPR (5.6%), 177 PR (71.4%), 25 NR (10%), 28 PD (11.3%). Collectively, objective response (OR) was 78.6% (CR + VGPR + PR). Five of the 271 study patients died before receiving any treatment and thus were excluded from survival analysis. The 4 years OS for all valid patients was 33.7% (median survival: 31.1 months; 95% CI: 24.3 -37.9), while EFS was 23.3% at a median follow up of 18.59 months (range: 0.2 -57.9 months). As 195 patients showed OR by end of induction; 94 underwent HSCT and their outcome was compared to the non transplant group (n = 101). Statistically significant higher OS (42.7%) was reported for transplant patients (median survival: 42.5 months; 95% CI: 34.1 -50.9) and EFS (35.6%), compared respectively to 27.6% (median survival: 20.5 months; 95% CI: 12.5 -28.5; P < 0.001) and 15.5% (P < 0.001) for the non transplant patients ( Table 2) .
Although statistically insignificant, both OS and EFS were at higher rates among patients received intensified induction with additional courses of "ICE" chemotherapy prior to HSCT (n = 28) compared to those who had no "ICE" before transplant (respectively, 57.2% v 36.8%; P = 0.312 and 47.9% v 30.3%; P = 0.128; median survival of 49 v 40.3 months).
Both OS and EFS were also correlated with response to induction therapy, extent of primary tumor resection, and INPC ( Table 2 ). Comparing induction responders (OR) to non-responders (NR and PD) there was a much superior OS and EFS for patients with OR (P = 0.00 and P = 0.001, respectively). The outcome was also better in patients underwent surgical resection of their primary tumor compared to others who did not; the OS and EFS were respectively 40% and 20.9% in the former versus 26% and 9.1% in the latter (P = 0.00, each). As well, a highly significant difference in survival rates was found between favorable and unfavorable INPC patients (respectively, 81.6% v 28.9%; P = 0.001 and 65.5% v 13.3%; P = 0.00). Amplification of NMYC gene compared to normal NMYC and NB histological subtype (P = 0.00 and P = 0.044, respectively).
In multivariate analysis each of; consolidation HSCT, post induction disease status (response), and INPC based pathology subtype was an independent prognostic variable predicting survival (Figures 2-4) .
On the other hand, EFS was significantly affected by stage, age, and CNS metastasis. Whereas EFS was 64.3% for stage 4S disease, it was respectively 42.4% and 8.1% for stages 3 and 4 (P = 0.00%). Patients younger than 18 months had EFS of 34.1% compared to 11.1% for older age patients ≥ 18 months (p = 0.047%).
Among secondary sites of metastasis, CNS was predictive of lower EFS in comparison to other sites (P = 0.002). Although statistically non significant; nominally higher OS was reported with mediastinal tumors (46.8%) compared to abdominal origin (34.1%), and other sites (25%), (P = 0.141).
The abdominal extra-adrenal sites had higher OS than adrenal tumors (46.6% vs. 30% respectively; P =0.183), and only a borderline significance of improvement in OS as well as EFS was related to radiation therapy to the primary and metastatic sites ( Table 2 ).
Discussion
Approximately, 40% of NB tumors are classified as HR using current risk stratification criteria that carry very poor outcomes despite the use of aggressive therapies 15]. Until recently, the best outcome reported for [ HR-NB was achieved with intensive combination induction chemotherapy and surgery; followed by myeloablative therapy, hematopoietic stem cell rescue, and cis-RA as a differentiating agent [16] . Our data showed that the 4 years OS for the entire HR-NB study patients was 33.7% and EFS of 23.3% including both transplant and non transplant patients. Similarly, an earlier Japanese NB study group reported a five-year OS outcome of 34.4% for stage 4 disease patients [17] , whereas a more recent study from Singapore reported a 5 years OS of only 28.2% for HR-NB [18] .
Significant survival benefit found in a subgroup of our patients was ought to HSCT. The OS for patients underwent HSCT (42.7%, n = 94) was significantly higher compared to those who did not (27.6%, n = 177; P < 0.001; Figure 2 ).
The EFS for transplanted patients (35.6%) was also significantly higher than for other patients received no transplant (15.5%; P < 0.001).
Consistently, in a well conducted prospective randomized clinical trial by Children's Oncology Group (COG), the EFS for patients randomly assigned to consolidation ABMT was significantly higher than for those randomly assigned to chemotherapy; the 5-year EFS was 30% ± 4% versus 19% ± 3%, respectively (P = 0.04).
Isoretinoin has independently resulted in a significantly improved OS when given following consolidation therapy. The 5-year OS of patients assigned to ABMT/ cis-RA was 59% ± 8%; versus 41% ± 7% for ABMT/no cis-RA [5] .
Chimeric anti-GD2 MAb (Ch14.18) tested in a large phase III COG randomized clinical trial in combination with IL-2 and GM-CSF; was associated with an improved 2 year EFS and OS in comparison to standard maintenance therapy (66% v 46% and 86% v 75%, respecttively) [19] .
As shown in Table 2 , Post induction OR had a statistically significant positive impact when compared to NR and PD; on both OS (43% v 12 %; P = 0.00) and EFS (18.4% v 11.2%; P = 0.001) that found to be in consistence with other investigators [20] . Our data also showed that OS and EFS were improved by resection of primary tumor compared to no or less than partial tumor resection; (40% v 26% and 20.9% v 9.1%, respectively; P = 0.00; each). Though previous reports mentioned a controversial role for aggressive tumor resection [21, 22] , improved local control and OS rates in correlation to complete gross resection of the primary tumor were reported by La Quaglia et al., in stage 4 NB [23] . This was contradicted in a recent Finnish study which reported that OS in HR-NB patients was rather related to objective chemotherapy response, while no significant impact was found for complete excision of the primary tumor [24] .
Unfavorable histological differentiation, amplified NMYC gene, CNS metastasis, and older age at diagnosis were all shown to have a significantly negative impact on the survival of our patients ( Table 2) .
While unfavorable INPC histology was associated with poorer OS and EFS than favorable subtype, CNS found to be the only metastatic site to show significant correlation to patients outcome as regards EFS (P = 0.002). Similarly, EFS was significantly lower among patients ≥ 18 months of age (P = 0.047) that was supported by other reports stated that age at diagnosis was one of the single most important indicators of survival in NB [3, 25] . Unfavorable clinical variables such as; age above18 months and advanced stage were found to be closely associated with poor biologic risk factors including unfavorable histopathology, MYCN amplification, 1p and 11q loss of heterozygosity, as well as other partial chromosomal deletions [26] .
Conclusion
In spite of aggressive therapy, HR-NB carried a discouraging survival outcome. The prognosis for high risk NB remained poor but myeloablative therapy followed by stem cell rescue is regarded as the most important goal of high risk NB treatment to improve survival till present. Each of consolidation HSCT, post induction disease status, as well as INPC-based pathological subtype was an independent predictive variable of survival. A collaborative effort with an emphasis on biologic characteristics of aggressive disease and tailored therapy needs to be strengthened to further our understanding of this disease.
